Evaluation of antiarrhythmic drug efficacy in patients with an ICD. Unlimited potential or replete with complexity and problems?

Détails

Ressource 1Télécharger: serval:BIB_FD087940F734.P001 (306.44 [Ko])
Etat: Public
Version: de l'auteur
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
ID Serval
serval:BIB_FD087940F734
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Evaluation of antiarrhythmic drug efficacy in patients with an ICD. Unlimited potential or replete with complexity and problems?
Périodique
European Heart Journal
Auteur(s)
Pratt  C. M., Camm  A. J., Bigger, J. T., Jr. , Breithardt  G., Campbell  R. W., Epstein  A. E., Kappenberger  L. J., Kuck  K., Pocock  S., Saksena  S., Waldo  A. L.
ISSN
0195-668X (Print)
Statut éditorial
Publié
Date de publication
11/1999
Volume
20
Numéro
21
Pages
1538-52
Notes
Journal Article
Review --- Old month value: Nov
Résumé
A report from a Study group, proposed by A. J. Camm, London, of the Working Groups on Arrhythmias and Cardiac Pacing of the European Society of Cardiology; co-sponsored by the North American Society of Pacing and Electrophysiology. The Study Group was convened on 29 August 1997 at Saltsjobaden, near Stockholm. The meeting was chaired by A. J. Camm, London, and C. M. Pratt, Houston. Based on the presentation and discussions, a first draft of the documents was prepared by C. Pratt and J. Camm which was then circulated to all members three times for their review. All members of the Study Group approved the final manuscript. This report represents the opinion of the members of this Study Group and does not necessarily reflect the official position of either society.The meeting of the Study Group was made possible by unrestricted educational grants from Medtronic, Guidant, Proctor & Gamble, Berlex and Sanofi.Also, presented, in part, at the Cardio-Renal Drugs Advisory Board meeting of the Food and Drug Administration, Bethesda, Maryland, on 30 April 1999.
Mots-clé
Anti-Arrhythmia Agents/*therapeutic use Arrhythmia/drug therapy/etiology/*therapy Cause of Death Clinical Protocols *Clinical Trials *Defibrillators, Implantable Evaluation Studies Humans Patient Selection Tachycardia/drug therapy Treatment Outcome
Pubmed
Web of science
Open Access
Oui
Création de la notice
15/02/2008 12:29
Dernière modification de la notice
25/09/2019 7:11
Données d'usage